Market capitalization | $730.96m |
Enterprise Value | $613.75m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 5.55 |
P/S ratio (TTM) P/S ratio | 6.62 |
P/B ratio (TTM) P/B ratio | negative |
Revenue growth (TTM) Revenue growth | 202.25% |
Revenue (TTM) Revenue | $110.50m |
As a Free StocksGuide user, you can view scores for all 6,912 stocks worldwide.
9 Analysts have issued a Wave Life Sciences Ltd. forecast:
9 Analysts have issued a Wave Life Sciences Ltd. forecast:
Jun '24 |
+/-
%
|
||
Net Profit | -74 -74 |
44%
44%
|
|
Depreciation and Amortization | 8.80 8.80 |
11%
11%
|
|
Stock Compensation | 11 11 |
4%
4%
|
|
Operating Cash Flow | -128 -128 |
1,084%
1,084%
|
|
Investments | 1.02 1.02 |
16%
16%
|
|
Dividend Paid | - - |
-
|
|
Free Cash Flow | -129 -129 |
972%
972%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Wave Life Sciences Ltd. is a biotechnology company, which engages in the development of proprietary synthetic chemistry drug. It focuses on the design, development, and commercialization of nucleic acid-based therapeutics. The company was founded by Gregory L. Verdine and Takeshi Wada on July 23, 2012 and is headquartered in Singapore.
Head office | Singapore |
CEO | Paul Bolno |
Employees | 268 |
Founded | 2012 |
Website | www.wavelifesciences.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.